Reuters logo
BRIEF-FDA grants accelerated approval to Durvalumab for treatment of patients with locally advanced or metastatic urothelial carcinoma
May 1, 2017 / 5:11 PM / 6 months ago

BRIEF-FDA grants accelerated approval to Durvalumab for treatment of patients with locally advanced or metastatic urothelial carcinoma

May 1 (Reuters) - U.S. FDA

* Grants accelerated approval to Durvalumab for treatment of patients with locally advanced or metastatic urothelial carcinoma

* Approved Ventana PD-l1 assay as complementary diagnostic for assessment of PD-l1 protein in formalin-fixed, paraffin-embedded urothelial carcinoma tissue Source text : [ID:bit.ly/2oYipOi] Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below